胶质母细胞瘤（GBM）临床治疗效果差，免疫治疗对多数患者疗效不佳。研究人员开展联合抗 PD-L1 和抗 VEGFR2 疗法治疗 GBM 的研究。结果显示该联合疗法可调节肿瘤微环境（TME），抑制 GBM 细胞免疫逃逸，延长小鼠生存期，为 GBM 治疗提供新思路。

This manuscript demonstrates that Oct4 overexpression synergizes with Notch inhibition (Rbpj knockout) to promote the conversion of adult murine Müller glia (MG) into bipolar cells. These findings are ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, P. R. China ...

从机制上看，COPA 敲除会增加富含亮氨酸的五肽重复序列含（LRPPRC）蛋白的降解，从而以 m6A 依赖的方式降低 DNA 结合抑制因子 3（ID3）mRNA 的稳定性 ... 结果表明，ID3 敲低导致 p16 和 p21 启动子激活，以及 p16 和 p21 表达上调，但对 p15 没有影响。为了进一步阐明 ...

膀胱癌治疗正面临三重困境：现有疗法响应率不足40%、耐药后治疗选择匮乏、动态监测手段缺失。在FGFR抑制剂领域，虽然厄达替尼作为首个获批的泛FGFR抑制剂改写治疗指南，但临床数据显示其客观缓解率仅32.2%，中位无进展生存期仅5.5个月。这种疗效瓶颈背后，是肿瘤细胞通过多通路逃逸建立的复杂防御体系。研究人员采用全基因组CRISPR筛选技术，在FGFR改变的膀胱癌细胞系中发现COPA基因缺失可使厄达 ...

本研究聚焦非小细胞肺癌（NSCLC）进展中的关键调控轴PAK1/TCF1，揭示其在肿瘤发生中的作用机制，为NSCLC治疗提供新靶点，具有 ...

AI-generated image of cancer being attacked by an mRNA vaccine. In the midst of the COVID-19 pandemic, scientists raced to develop vaccines in record time. The first reliable vaccines, using ...

The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030.

Get Instant Summarized Text (Gist) The NIH has reportedly advised scientists to omit mRNA vaccine references from grant applications, suggesting a potential shift away from this research area ...